ReviewCancers2025

Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis.

Fernando M Runzer-Colmenares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.